Lobbying disclosures · Lobbying report
DVA: second_quarter 2026 lobbying report
Issues related to Medicare ESRD payments and policy, including Medicare Advantage. Medicare reimbursement and Medicare Secondary Payer policies, including H.R. 2199 and S.1173.
Follow DVA- Became public
- Jul 20, 2026, 9:56 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 10, 2026, 4:21 PM EST
Why this is connected
Exact legal-name match: DAVITA INC. (https://www.sec.gov/Archives/edgar/data/927066/).
Reported lobbying amounts
Income: $60,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/65d04d42-593a-4c0e-8445-8032fa926acd/","filing_uuid":"65d04d42-593a-4c0e-8445-8032fa926acd","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/65d04d42-593a-4c0e-8445-8032fa926acd/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Tazeen Ahmad","dt_posted":"2026-07-20T21:56:43-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"926 Pennsylvania Ave, SE","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20003","registrant":{"id":72053,"url":"https://lda.gov/api/v1/registrants/72053/","house_registrant_id":35843,"name":"CAPITOL HILL CONSULTING GROUP","description":"Government Relations Firm","address_1":"926 Pennsylvania Ave, SE","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20003","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"TAZEEN AHMAD","contact_telephone":"+1 202-488-0101","dt_updated":"2026-08-17T10:56:59.984637-04:00"},"client":{"id":165693,"url":"https://lda.gov/api/v1/clients/165693/","client_id":1005790,"name":"DAVITA INC","general_description":"healthcare company","client_government_entity":false,"client_self_select":null,"state":"CO","state_display":"Colorado","country":"US","country_display":"United States of America","ppb_state":"CO","ppb_state_display":"Colorado","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2015-02-11"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to Medicare ESRD payments and policy, including Medicare Advantage. Medicare reimbursement and Medicare Secondary Payer policies, including H.R. 2199 and S.1173.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":61615,"prefix":null,"prefix_display":null,"first_name":"BRIAN","nickname":null,"middle_name":null,"last_name":"SUTTER","suffix":null,"suffix_display":null},"covered_position":"Staff Dir., W&M Health Subcommittee, Chrman Dave Camp April'13-Dec.'14 Professional Staff, W&M Health Subcommittee, Chrman Dave Camp, Jan'11-April'13 Leg Dir. Rep. Dave Camp, May'08-Jan'11 Leg Asst Rep. Dave Camp, Feb'03-May'08; Staff Ast July'02-","new":false},{"lobbyist":{"id":71228,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":"ELIZABETH","last_name":"WILKINSON-HOLLAND","suffix":null,"suffix_display":null},"covered_position":"Staff -Rep. Price (2010-11), LA: Rep. Grimm (2011-12), Rep. Black (2012-13), Sen.Vitter (2013-2015), Sen. Heller (2015-17), Policy Adv. to the Sec.- Dept of HHS (3/2017-8/2017), Sr Advisor to Administrator - Ctrs for Medicare & Medicaid (8/17- 5/19)","new":false},{"lobbyist":{"id":141629,"prefix":"mr","prefix_display":"MR.","first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"DAVIS","suffix":null,"suffix_display":null},"covered_position":"Staff Assistant, Legislative Assistant, Senior Legislative Assistant, and Legislative Director - Rep. Rick Boucher (2006-2011)","new":true},{"lobbyist":{"id":150427,"prefix":null,"prefix_display":null,"first_name":"KIMBERLEE","nickname":null,"middle_name":null,"last_name":"TRZECIAK","suffix":null,"suffix_display":null},"covered_position":"FDA. Dep. Commissioner; 8/23-1/25. Assoc. Commissioner Leg. Affairs; 2/2022-08/2023. House Com. Energy & Commerce: Chief Health Advisor, 2/22-4/19. Sen. Health Policy Advisor, 3/19-3/15. Rep. John D. Dingell - LD, 05/13-07/11. Sen. LA, 7/11-08/09, LA","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in DVA
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Aug 5, 2026$1K–$15K
Rep. Julie Johnson (D-TX-32)
$1K–$15K · Traded Sep 23, 2025 · disclosed Aug 5, 2026 · Joint · filed 316 days later
- Aug 5, 2026$1K–$15K
Rep. Julie Johnson (D-TX-32)
$1K–$15K · Traded Sep 23, 2025 · disclosed Aug 5, 2026 · Joint · filed 316 days later
- Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Oct 7, 2025$1K–$15K
Rep. Julie Johnson (D-TX-32)
$1K–$15K · Traded Sep 25, 2025 · disclosed Oct 7, 2025 · Joint
- Jan 17, 2024$1K–$15K
Sen. Jerry Moran (R-KS)
$1K–$15K · Traded Dec 14, 2023 · disclosed Jan 17, 2024
- Jan 17, 2024$1K–$15K
Sen. Jerry Moran (R-KS)
$1K–$15K · Traded Dec 14, 2023 · disclosed Jan 17, 2024 · Spouse
- Jan 12, 2024$1K–$15K
Sen. Tommy Tuberville (R-AL)
$1K–$15K · Traded Dec 12, 2023 · disclosed Jan 12, 2024 · Joint
- Jul 14, 2023$1K–$15K
Sen. Tommy Tuberville (R-AL)
$1K–$15K · Traded Jun 12, 2023 · disclosed Jul 14, 2023 · Joint
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.